Atlas Trials

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Clinical trial NCT07708961 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07708961
Sponsor
Mayo Clinic
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Glioblastoma, IDH-Wildtype
Start date
2026-08-16
Primary completion
2036-07-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.